Table 2.
Outcomes and subgroup comparisons; significant results in red.
| Outcomes | n | R (%) | TTR, median [IQR] | CR (%) | TTCR, median [IQR] | Second line needed (%) | Treatment at day 90 (%) | Platelets, 10 × 109/L [IQR] | ||
|---|---|---|---|---|---|---|---|---|---|---|
| At diagnosis | Day 30 | Day 90 | ||||||||
| Overall | 50 | 45/47 (96) | 4 [2-6] | 40/45 (89) | 7 [4-15.8] | 17/50 (34) | 14/30 (47) | 7 [4-13] | 111 [44-175] | 175 [62-218] |
| ChAd | 40 | 35/37 (95) | 3.5 [2-6.8] | 31/36 (86) | 6.5 [4-22.8] | 16/40 (40) | 11/25 (44) | 7.5 [3.3-14.5] | 108 [42.5-177] | 131.5 [60.3-215] |
| BNT | 10 | 10/10 (100) | 4 [2-5.8] | 9/9 (100) | 7 [5-14] | 1/10 (10) | 3/5 (60) | 5 [3.3-9] | 122.5 [41-157] | 202 [115-246.5] |
| De novo | 37 | 32/34 | 4 [2-11] | 30/33 | 7.5 [4-28.3] | 14/37 | 12/24 | 7 [3-15] | 116 [40-171.3] | 175 [67-214] |
| Relapsed | 13 | 13/13 | 4 [2-4] | 10/12 | 5 [4-6.3] | 3/13 | 2/6 | 6 [4.5-11.5] | 77 [44.5-224.5] | 82 [47.5-205.5] |
| First dose | 42 | 37/39 | 4 [2-8] | 32/37 | 6.5 [4-19] | 13/42 | 11/26 | 7.5 [3-16] | 123 [63-176] | 175 [67-214] |
| Second dose | 8 | 8/8 | 3 [2.3-4.8] | 8/8 | 7 [4.5-20] | 4/8 | 3/4 | 5 [4-8] | 40 [22-170] | 164 [51-288] |
| Flu vaccine | 5 | 5/5 | 18 [2.5-59] | 5/5 | 23 [6.5-59] | 3/5 | 1/3 | 5 [1.5-38] | 144 [46-168] | 163 [90-282] |
| No flu vaccine | 45 | 40/42 | 4 [2-5.5] | 35/40 | 6 [4-15] | 14/45 | 13/27 | 7 [4-13] | 110 [43-175] | 175 [55-218] |
| Plt <10x109/L at presentation | 35 | 31/33 | 4 [2-6] | 27/32 | 6.5 [4-15] | 15/35 | 12/21 | 3 [1-5] | 121 [32-175] | 180 [55-220] |
| Plt ≥10x109/L | 15 | 14/14 | 4 [2-12] | 13/13 | 7 [4.8-30] | 2/15 | 2/9 | 15 [12-27] | 108 [74-170] | 110 [71-204] |
| Presentation from vaccination | ||||||||||
| <7 d | 12 | 12/12 | 3 [2-4.8] | 10/12 | 6 [3.8-9.3] | 5/12 | 6/7 | 7 [5-8] | 53 [34-138] | 82 [49-181] |
| ≥7 d | 38 | 33/35 | 4 [2-7.3] | 30/33 | 7 [4-22] | 12/38 | 8/23 | 7 [3-14] | 125 [73-178] | 178 [74-232] |
| <14 d | 23 | 23/23 | 4 [3-8] | 18/22 | 7 [5-37] | 8/23 | 8/14 | 5 [3-8] | 73 [26-151] | 146 [54-207] |
| ≥14 d | 37 | 22/24 | 3 [2-5] | 22/23 | 6 [4-18] | 9/27 | 6/16 | 10 [4-17] | 138 [104-178] | 175 [65-227] |
| Treatment | ||||||||||
| Prednisone | 31 | 28/29 | 3.5 [2-5.8] | 27/28 | 7 [5-15] | 11/31 | 10/17 | 5 [3-13] | 149 [93-206] | 180 [82-220] |
| Dexamethasone | 12 | 11/12 | 2.5 [2-4] | 10/12 | 3 [3-41] | 6/12 | 4/9 | 5 [3.3-10] | 36 [19-91] | 85 [33-211] |
| IVIg used | 33 | 31/32 | 3 [2-5] | 30/32 | 7 [4-12] | 14/33 | 11/20 | 5 [3-11] | 135 [48-178] | 178 [60-219] |
| No IVIg | 17 | 14/15 | 4.5 [4-27] | 10/13 | 18 [4.5-45] | 3/17 | 3/10 | 12 [5-27] | 75 [20-110] | 112 [71-230] |
CR, complete response; IVIg, intravenous immunoglobulin; TTCR, time to complete response; TTR, time to response.